医学
性病学
皮肤病科
硫唑嘌呤
大疱性类天疱疮
氨苯砜
强的松
指南
类天疱疮
甲氨蝶呤
疾病
外科
内科学
免疫学
病理
抗体
作者
Luca Borradori,Nina van Beek,Claudio Feliciani,Billal Tedbirt,Emiliano Antiga,Richard N. Bergman,Barbara C. Böckle,Marzia Caproni,F. Caux,Nisha Suyien Chandran,Giuseppe Cianchini,Maryam Daneshpazhooh,Dipankar De,Dario Didona,Giovanni Di Zenzo,Marian Dmochowski,Kossara Drenovska,Jan Ehrchen,Matthias Goebeler,Richard Groves
摘要
Abstract Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo‐like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. Objectives and methodology The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence‐based or rely on expert opinion. The degree of consent among all task force members was included. Results Treatment depends on the severity of BP and patients' comorbidities. High‐potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B‐cell‐depleting therapy and intravenous immunoglobulins may be considered in treatment‐resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. Conclusions The guidelines for the management of BP were updated. They summarize evidence‐ and expert‐based recommendations useful in clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI